Review| Volume 20, ISSUE 11, P1482-1485, November 2013

Download started.


Memantine hydrochloride in the treatment of dementia subtypes


      Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer’s disease (AD). We conducted a review of the literature to determine the changes to the central glutamatergic neurotransmitter system in dementia subtypes and the available clinical evidence regarding the use of memantine in the treatment of different dementia subtypes. We conclude from our review that memantine may be an effective therapeutic option in managing AD, frontotemporal dementia, dementia with Lewy bodies, Parkinson’s disease dementia and vascular dementia. When a diagnosis of the dementia subtype cannot be clearly identified or when there is no clear therapeutic option, memantine may be simple and safe.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Neuroscience
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Davydova T.V.
        • Voskresenskaya N.I.
        • Gorbatov V.Y.
        • et al.
        Production of autoantibodies to glutamate during Alzheimer’s dementia.
        Bull Exp Biol Med. 2009; 147: 405-407
        • Rupsingh R.
        • Borrie M.
        • Smith M.
        • et al.
        Reduced hippocampal glutamate in Alzheimer disease.
        Neurobiol Aging. 2011; 32: 802-810
        • Tsang S.W.
        • Vinters H.V.
        • Cummings J.L.
        • et al.
        Alterations in NMDA receptor subunit densities and ligand binding to glycine recognition sites are associated with chronic anxiety in Alzheimer’s disease.
        Neurobiol Aging. 2008; 29: 1524-1532
        • Dabir D.V.
        • Robinson M.B.
        • Swanson E.
        • et al.
        Impaired glutamate transport in a mouse model of tau pathology in astrocytes.
        J Neurosci. 2006; 26: 644-654
        • Ernst T.
        • Chang L.
        • Melchor R.
        • et al.
        Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy.
        Radiology. 1997; 203: 829-836
        • Procter A.W.
        • Qurne M.
        • Francis P.T.
        Neurochemical features of frontotemporal dementia.
        Dement Geriatr Cogn Disord. 1999; 10: 80-84
        • Francis P.T.
        • Perry E.K.
        Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies.
        Mov Disord. 2007; 22: S351-S357
        • Aarsland D.
        • Ballard C.
        • Walker Z.
        • et al.
        Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
        Lancet Neurol. 2009; 8: 613-618
        • Picconi B.
        • Piccoli G.
        • Calabresi P.
        Synaptic dysfunction in Parkinson’s disease.
        Adv Exp Med Biol. 2012; 970: 553-572
        • Kirvell S.L.
        • Elliott M.S.
        • Kalaria R.N.
        • et al.
        Vesicular glutamate transporter and cognition in stroke: a case-control autopsy study.
        Neurology. 2010; 75: 1803-1809
        • Shiino A.
        • Watanabe T.
        • Shirakashi Y.
        • et al.
        The profile of hippocampal metabolites differs between Alzheimer’s disease and subcortical ischemic vascular dementia, as measured by proton magnetic resonance spectroscopy.
        J Cereb Blood Flow Metab. 2012; 32: 805-815
        • Francis P.T.
        Altered glutamate neurotransmission and behaviour in dementia: evidence from studies of memantine.
        Curr Mol Pharmacol. 2009; 2: 77-82
        • Kutzing M.K.
        • Luo V.
        • Firestein B.L.
        Protection from glutamate-induced excitotoxicity by memantine.
        Ann Biomed Eng. 2012; 40: 1170-1181
        • Hort J.
        • O’Brien J.T.
        • Gainotti G.
        • et al.
        EFNS guidelines for the diagnosis and management of Alzheimer’s disease.
        Eur J Neurol. 2010; 17: 1236-1248
        • Rabins P.V.
        • Blacker D.
        • et al.
        • APA Work Group on Alzheimer’s Disease and other Dementias
        American Pychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition.
        Am J Psychiatry. 2007; 164: 5-56
        • Herrmann N.
        • Li A.
        • Lanctôt K.
        Memantine in dementia: a review of the current evidence.
        Expert Opin Pharmacother. 2011; 12: 787-800
        • Kerchner G.A.
        • Tartaglia M.C.
        • Boxer A.
        Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
        Expert Rev Neurother. 2011; 11: 709-717
        • Aarsland D.
        • Ballard C.
        • Rongve A.
        • et al.
        Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia.
        Curr Neurol Neurosci Rep. 2012; 12: 492-501
        • Leroi I.
        • Overshott R.
        • Byrne E.J.
        • et al.
        Randomized controlled trial of memantine in dementia associated with Parkinson’s disease.
        Mov Disord. 2009; 24: 1217-1221